SCHEMBL4433437

SCHEMBL4433437

CCCCCC(Cl)CC(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 11/20 0.59
FFAR1 O14842 3/20 0.47
FFAR4 Q5NUL3 2/20 0.47
PPARD Q03181 7/20 0.45
MAPT P10636 1/20 0.45
LCK P06239 1/20 0.45
ZDHHC20 Q5W0Z9 1/20 0.45
ZDHHC2 Q9UIJ5 1/20 0.45
AKR1B1 P15121 1/20 0.44
PPARG P37231 6/20 0.43
PPARA Q07869 6/20 0.43
HDAC11 Q96DB2 5/20 0.43
TSHR P16473 4/20 0.43
ALDH1A1 P00352 2/20 0.43
TLR2 O60603 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
FABP4 P15090 2/20 0.43
PTPN1 P18031 2/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
SLC22A8 Q8TCC7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29893958 1.00 GPR84 (0.59) GPR84FFAR1FFAR4PPARDMAPT
SCHEMBL6463301 1.00 GPR84 (0.59) GPR84FFAR1FFAR4PPARDMAPT
SCHEMBL29894891 0.98 GPR84 (0.62) GPR84FFAR1FFAR4PPARDMAPT
SCHEMBL6463845 0.98 GPR84 (0.62) GPR84FFAR1FFAR4PPARDMAPT
SCHEMBL1158455 0.98 GPR84 (0.62) GPR84FFAR1FFAR4PPARDMAPT
SCHEMBL6465804 0.98 GPR84 (0.62) GPR84FFAR1FFAR4PPARDMAPT
SCHEMBL28499460 0.98 GPR84 (0.62) GPR84FFAR1FFAR4PPARDMAPT
SCHEMBL6466759 0.98 GPR84 (0.62) GPR84FFAR1FFAR4PPARDMAPT
SCHEMBL6461561 0.98 GPR84 (0.62) GPR84FFAR1FFAR4PPARDMAPT
SCHEMBL6461000 0.93 GPR84 (0.50) GPR84FFAR1FFAR4PPARDAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120117984-A Preparation method of 6-hydroxy-8-chlorooctanoate 江西联陆生物科技有限公司 2025-06-10 CN disclosed
US-20210289794-A1 COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-23 US disclosed
EP-2125031-B1 LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS MARINA BIOTECH INC (US) 2017-11-01 EP disclosed
US-8193246-B2 Lipids and lipid assemblies comprising transfection enhancer elements MARINA BIOTECH, INC. (US) 2012-06-05 US disclosed
EP-2125031-A2 LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS Novosom AG (DE) 2009-12-02 EP disclosed
US-20080306153-A1 Lipids and lipid assemblies comprising transfection enhancer elements CEQUENT PHARMACEUTICALS, INC. 2008-12-11 US disclosed
WO-2008074487-A2 LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS NOVOSOM AG (DE) 2008-06-26 WO disclosed
US-6903233-B2 Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester TAKASAGO INTERNATIONAL CORPORATION (JP) 2005-06-07 US disclosed
US-20030225301-A1 Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester TAKASAGO INTERNATIONAL CORPORATION (JP) 2003-12-04 US disclosed
EP-1367067-A1 Highly water-absorptive ophthalmic lens and method of producing the same Menicon Co., Ltd. (JP) 2003-12-03 EP disclosed
US-20030218717-A1 Highly water-absorptive ophthalmic lens and method of producing the same MENICON CO., LTD. (JP) 2003-11-27 US disclosed
EP-1344763-A1 Process for producing optically active 3-halogenocarboxylic acid esters and 3-azide-carboxylic acid esters Takasago International Corporation (JP) 2003-09-17 EP disclosed
EP-0799830-B1 Imidazothiazol derivatives as components of liquid crystalline mixtures ROLIC AG (CH) 2002-05-29 EP disclosed
US-5851425-A Imidazothiazoles ROLIC AG (CH) 1998-12-22 US disclosed
EP-0799830-A1 Imidazothiazol derivatives as components of liquid crystalline mixtures Rolic AG (CH) 1997-10-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225301-A1 Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester HDHD5, APEH, AOC3 GPR84 3209/4885FFAR1 349/4885FFAR4 507/4885
US-20080306153-A1 Lipids and lipid assemblies comprising transfection enhancer elements SREBF1, SREBF2, ELOVL1 GPR84 3559/4885FFAR1 1005/4885FFAR4 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.